Systemic effects of cancer: Role of multiple proteases and their toxic peptide products

Medical Science Monitor

Volumn 11, Issue 7, 2005, Pages

  Rubin, Harry ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer cachexia; Cathepsins; Lipolysis; Proteolysis

Indexed keywords

CATHEPSIN; CATHEPSIN L; FIBRIN DEGRADATION PRODUCT; PROTEASOME; PROTEINASE; UBIQUITIN;

ADIPOSE TISSUE; ADVANCED CANCER; CACHEXIA; CANCER PATIENT; CAUSE OF DEATH; CORRELATION ANALYSIS; FIBRINOGEN METABOLISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIPOLYSIS; NONHUMAN; PH; PROTEIN ANALYSIS; PROTEIN DEGRADATION; REVIEW;

ADIPOSE TISSUE; ANIMALS; CACHEXIA; CATHEPSINS; ENZYME ACTIVATION; FIBRINOGEN; HUMANS; IMMUNE TOLERANCE; LIPOLYSIS; NEOPLASMS; PEPTIDE HYDROLASES; PEPTIDES;

EID: 22244432194     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst, 1997; 89: 1763-73
2. Zucker S, Lysik RM, DeStefano JF: Cancer cell inhibition of erythropoiesis. J Lab Clin Med, 1980; 96: 770-82
3. Glasgow AH, Nimberg RB, Menzoian JO et al: Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer. N Engl J Med, 1974; 291: 1263-67
4. DeWys WD, Begg C, Lavin PT et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med, 1980; 89: 491-97
5. Klastersky J, Daneau D, Verhest A: Causes of death in patients with cancer. Eur J Cancer, 1972; 8: 149-54
6. Greenstein JR: Biochemistry of Cancer. New York, NY, Academic Press, Inc., 1954
7. Nakahara W, Fukuoka F: The newer concept of cancer toxin. Adv in Cancer Res, 1958; 5: 157-77
8. Costa G: Cachexia, the metabolic component of neoplastic diseases. Prog Exp Tumor Res, 1963; 3: 321-69
9. Nakahara W, Fukuoka F: A toxic cancer tissue constituent as evident by its effect on liver catalase activity. Japan Med J, 1948; 1: 271-77
10. Nakahara W, Fukuoka F: Toxohormone: A characteristic toxic substance produced by cancer tissue. GANN, 1949; 40: 45-69
11. Yunoki K, Griffin AC: Composition and properties of a highly purified toxohormone preparation. Cancer Res, 1961; 21: 537-44
12. Goodlad GAJ, Raymond MJ: The action of the Walker 256 carcinoma and toxohormone on amino acid incorporation into diaphragm protein. Eur J Cancer, 1973; 9: 139-46
13. Yamazaki H, Nitta K, Umezawa H: Immunosuppression induced with cell-free fluid of Ehrlich carcinoma ascites and its fractions. GANN, 1973; 64: 83-92
14. Blakeslee D, Raymond MJ, Ward T, Bandy P: Isolation of a factor with toxohormone properties from mouse tumor cells in culture. Cancer Lettersm, 1978; 5: 49-54
15. Sylvén B, Holmberg B: On the structure and biological effects of a newly-discovered cytotoxic polypeptide in tumor fluid. Eur J Cancer, 1965; 1: 199-202
16. Nimberg RB, Glasgow AH, Menzoian JO et al: Isolation of immunosuppressive peptide fraction from the serum of cancer patients. Cancer Res, 1975; 35: 1489-94
17. Badger AM, Cooperband SR, Merluzzi VJ, Glasgow AH: Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum. Cancer Res, 1977; 37: 1220-26
18. Rubin H: Cancer cachexia: Its correlations and causes. Proc Natl Acad Sci USA, 2003; 100: 5384-89
19. Rubin H: The inhibition of chick embryo cell growth by medium obtained from cultures of Rous sarcoma cells. Exp Cell Res, 1966; 41: 149-61
20. Rubin H: The suppression of morphological alterations in cells infected with Rous sarcoma virus. Virology, 1960; 12: 14-31
21. Astrup T, Alkjaersig N: Classification of proteolytic enzymes by means of their inhibitors. Nature, 1952; 169: 314-16
22. Unkeless JC, Tobia A, Ossowski L et al: An enzymatic function associated with transformation of fibroblasts by oncogenic viruses I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med, 1973; 137: 85-111
23. Quigley JP, Ossowski L, Reich E: Plasminogen, the serum proenzyme activated by factors from cells transformed by oncogene viruses. J Biol Chem, 1974; 249: 4306-11
24. Ossowski L, Unkeless JC, Tobia A et al: An enzymatic function associated with transformation of fibroblasts by oncogenic viruses II. Mammalian fibroblast cultures transformed by DNA and RNA tumor viruses. J Exp Med, 1973; 137: 112-26
25. Ossowski L, Quigley JP, Reich E: Fibrinolysis associated with oncogenic transformation: Morphological correlates. J Biol Chem, 1974; 249: 4312-20
26. Stetler-Stevenson WG, Aznavoorian S, Liotta L: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann Rev Cell Biol, 1993; 9: 541-73
27. McCawly LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Molecular Medicine Today, 2000; 6: 149-56
28. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nature Reviews/Cancer, 2002; 2: 161-74
29. Kitada S, Mwasi L, Mead JF: Liver and thymus lipid composition in AKR mice with and without lymphomas. Lipids, 1978; 13: 454-67
30. Kitada S, Hayes EF, Mead JF: Characterization of a lipid mobilizing factor from tumors. Progress in Lipid Res, 1981; 20: 823-26
31. Taylor DD, Gercel-Taylor C, Jenis LG, Devereux DF: Identification of a human tumor-derived lipolysis-promoting factor. Cancer Res, 1992; 52: 829-34
32. Beck SA, Mulligan HD, Tisdale MJ: Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst, 1990; 82: 1922-26
33. Das PC, Allan AGE, Woodfield DG, Cash JD: Fibrin degradation products in sera of normal subjects. Brit Med J, 1967; 4: 718-20
34. Hedner U, Nilsson IM: Clinical experience with determination of fibrinogen degradation products. Acta Med Scand, 1971; 189: 471-77
35. Triantaphyllopoulos E: The micromolecular fibrinogen derivatives: frationation by ultrafiltration and cation-exchange chromatography. Preparative Biochem, 1973; 3: 451-72
36. Price VE, Greenfield RE: Anemia in cancer. Adv Cancer Res, 1958; 5: 199-290
37. Carlsson S: Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand, 1973; 139: 499-502
38. Unkeless J, Dano K, Kellerman GM, Reich E: Fibrinolysis associated with oncogene transformation: Partial purification and characterization of die cell factor, a plasminogen activator. J Biol Chem, 1974; 249: 4295-305
39. Whittaker MG, Rees K, Clark CG: Reduced lymphocyte transformation in breast cancer. Lancet, 1971; i: 892-93
40. Scheurlen PG, Schneider W, Pappas A: Inhibition of transformation of normal lymphocytes by plasma factor from patients with Hodgkin's disease and cancer. Lancet, 1971; ii: 1265
41. Girmann G, Pees H, Schwarze G, Scheurlen PG: Immunosuppression by micromolecular fibrinogen degradation products in cancer. Nature, 1976; 259: 399-401
42. Maver ME, Mider GB, Johnson JM, Thompson JW: The comparative proteinase and peptidase activities of rat hepatoma and normal and regenerating rat liver. JNCI, 1946; 2: 277-82
43. Sylvén B, Malmgren H: The histological distribution of proteinase and peptidase activity in solid tumor transplants; a histochemical study on the enzymic characteristics of the different tumor cell types. Acta Radiologica Supplementum, 1957; 154: 1-124
44. Maxfield FR: Acidification of endocytic vesicles and lysosomes. In: Pastan I, Willingham MC (ed.), Endocytosis, New York, Plenam Press, 1985
45. Anson ML: The estimation of pepsin, trypsin, papain, and cathepsin with hemoglobin. J Gen Physiol, 1938; 22: 79-89
46. Libenson L, Jena M: Catheptic activity of blood serum in cancer. Cancer, 1957; 10: 1001-7
47. Sylvén B, Bois-Svensson I: On the chemical pathology of interstitial fluid I. Proteolytic activities in transplanted mouse tumors. Cancer Res, 1965; 24(4): 458-68
48. Sylvén B: Lysosomal enzyme activity in the interstitial fluid of solid mouse tumour transplants. Europ J Cancer, 1968; 4: 463-74
49. Holmberg B: On the in vitro release of cytoplasmic enzymes from ascites tumor cells as compared with strain L cells. Cancer Res, 1961; 21: 1386-93
50. Ryan RE, Crissman JD, Honn KV, Sloane BF: Cathepsin B-like activity in viable tumor cells isolated from rodent tumors. Cancer Res, 1985; 45: 3636-41
51. Rozhin J, Robinson D, Stevens MA et al: Properties of a plasma membrane-associated cathepsin B-like cysteine proteinase in metastatic B16 melanoma variants. Cancer Res, 1987; 47: 6620-28
52. Sameni M, Moin K, Sloane BF: Imaging proteolysis by living human breast cancer cells. Neoplasia, 2000; 2: 496-504
53. Sloane BF, Moin K, Krepela E, Rozhin J: Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer and Metastasis Reviews, 1990; 9: 333-52
54. Buck MR, Karustis DG, Day NA et al: Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J, 1992; 282: 273-78
55. Thorpe SM, Rochefort H, Garcia M et al: Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res, 1989; 49: 6008-14
56. Rochefort H, Capony F, Garcia M, Cathepsin D: A protease involved in breast cancer metastasis. Cancer and Metastasis Reviews, 1990; 9: 321-31
57. Glondu M, Llaudet-Coopman E, Derocq D et al: Down regulation of cathepsin D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene, 2002; 21: 5127-34
58. Gottesman M: The transformation-dependent secretion of a low molecular weight protein by murine fibroblasts. Proc Natl Acad Sci USA, 1978; 75: 2767-71
59. Denhardt DT, Hamilton RT, Parfett CLJ et al: Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins. Cancer Res, 1986; 46: 4590-93
60. Gal S, Gottesman M: The major excreted protein (MEP) of transformed mouse cells and cathepsin L have similar protease specificity. Biochem & Biophys Res Communications, 1986; 139: 156-62
61. Denhardt DT, Greenberg AH, Egan SE, Hamilton RT: Cathepsin L expression correlates closely with the metastatic potential of H-ras transformed murine fibroblasts. Oncogene, 1987; 2: 55-59
62. Gal S, Gottesman M: The major excreted protein of transformed fibroblasts is an activable acid-protease. J Biol Chem, 1986; 261: 1760-65
63. Young PR, Spevacek SM: Substratum acidification by murine B16F10 melanoma cultures. Biochimica et Biophysica Acta, 1992; 1139: 163-66
64. Young PR, Spevacek SM: Substratum acidification and proteinase activation by murine B16F10 melanoma cultures. Biochimica et Biophysica Acta, 1993; 1182: 69-74
65. Montcourrier P, Mangeat PH, Valembois C et al: Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Science, 1994; 107
66. Rochefort H, Liaudet-Coopman E: Cathepsin D in cancer metastasis: A protease and a ligand. APMIS, 1999; 107: 86-95
67. Heuser J: Changes in lysosome shape and distribution correlated with changes in cytoplasmic pH. J Cell Biol, 1989; 108: 855-64
68. Rozhin J, Sameni M, Ziegler G, Sloane BF: Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res, 1994; 54: 6517-25
69. Ghadially FN: Ultrastructure of the liver of the tumor-bearing host. Cancer, 1964; 18: 485-95
70. Scherstén T, Wahlqvist L, Johansson L-G: Lysomal enzyme activity in liver tissue from patients with renal carcinoma. Cancer, 1969; 23: 608-15
71. Scherstén T, Lundholm K: Lysomal enzyme activity in muscle tissue from patients with malignant tumors. Cancer, 1972; 30: 1246-51
72. Lundholm K, Bylund A-C, Holm J, Scherstén T: Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer, 1976; 12: 465-73
73. Jagoe RT, Redfern PF, Roberts RG et al: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clinical Science, 2002; 102: 353-61
74. Williams A, Sun X, Fischer JE, Hasseigren P-O: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery, 1999; 126: 744-50
75. Bossola M, Muscaritoli M, Costelli P et al: Increased muscle ubiquitin mRNA levels in gastric cancer patients. Amer J Physiol Regulatory Integrative Comp Physio, 2001; 280: R1518-23
76. Bossola M, Muscaritoli M, Costelli P et al: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg, 2003; 237: 384-89
77. Kitada S, Hayes EF, Mead JF, Zabin I: Lipolysis induction in adipocytes by a protein from tumor cells. J Cellular Biochem, 1982; 20: 409-16
78. Masuno H, Yoshimura H, Ogawa N, Okuda H: Isolation of a lipolytic factor (toxohormone-L) from ascites fluid of patients with hepatoma and its effect on feeding behavior. Eur J Cancer Clinical Oncol, 1984; 20: 1177-85
79. Temparis S, Aseni M, Taillandier D et al: Increased ATP-ubiquitin- dependent proteolysis in skeletal muscles of tumor-bearing rats. Cancer Res, 1994; 54: 5568-73
80. Llovera M, Garcia-Martinez C, Agell N et al: Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer, 1995; 61: 138-41
81. Baracos VE, DeVivo C, Hoyle DHR, Goldberg AL: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hematoma. Amer J Physiol, 1995; 31: e996-e1006
82. Mitch WE, Goldberg AL: Mechanisms of muscle wasting: The role of the ubiquitin-proteasome pathway. Mechanisms of Disease, 1996; 335: 1897-905
83. Prehn RT: Tumor progression and homeostasis. Adv Cancer Res, 1976; 23: 203-36
84. Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Brit J Cancer, 1976; 33: 241-59
85. Brodt P. Tumor immunology - three decades in review. Ann Rev Microbiol, 1983; 37: 447-76
86. Tisdale MJ: Cachexia in cancer patients. Nature Reviews, 2002; 2: 862-71
87. Socher SH, Martinez D, Craig JB et al: Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst, 1988; 80: 595-98
88. Saarinen UM, Koskelo E-K, Teppo A-M, Siimes M: Tumor necrosis factor in children with malignancies. Cancer Res, 1990; 50: 592-95
89. Maltoni M, Fabbri L, Nanni O et al: Serum levels of tumor necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer, 1997; 5: 130-35
90. Fearon KCH, Moses AGW: Cancer cachexia. Intl J Cardiology, 2002; 85: 73-81
91. Rubin H: Complementary approaches to understanding the role of proteases and their natural inhibitors in neoplastic development: Retrospect and prospect. Carcinogenesis, 2003; 24: 803-14
92. Goldé A: Chemical changes in chick embryo cells infected with Rous sarcoma virus in vitro. Virology, 1962; 16: 9-20
93. Han J, Ohno N, Pasco S et al: A cell binding domain from the a3 chain of type IV collagen inhibits proliferation of melanoma cells. J Biol Chem, 1997; 272: 20395-401
94. Maeshima Y, Colorado PC, Torre A et al: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem, 2000; 273: 21340-48
95. Maeshima Y, Yerramalla UL, Dhanabal M et al: Extracellular matrix-derived peptide binds to avb3 integrin and inhibits angiogenesis. J Biol Chem, 2001; 276: 31959-68
96. Hamano Y, Zeisberg M, Sugimoto H et al: Physiological levels of tumstatin, a fragment of collagen IV a3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via avb3 integrin. Cancer Cell, 2003; 3: 589-601
97. Coussens LM, Singleton, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 2002; 295: 2387-92